Literature DB >> 15875784

Novel insights into the mechanism of action of intravesical immunomodulators.

Dionisios N Mitropoulos1.   

Abstract

To date, the precise mechanism of intravesical immunomodulators remains unknown. In vitro, interferon alpha (IFN-alpha) acts directly on neoplastic cells and inhibits their proliferation while it induces their differentiation. Urothelium and transitional cell carcinoma (TCC) cells express IFN-alpha receptor, the density of which correlates with lesion grade. IFN-alpha reduces neo-microvascular density in the normal urothelium adjacent to the tumor after transurethial resection (TUR), possibly via inhibition of COX-1. Moreover, IFN-alpha induces the membrane expression of tumor-related antigens and MHC antigens, providing a basis for a cellular immune response. When given intravesically, IFN-alpha may result in local and systemic T cell and NK cell activation. By monitoring nitric oxide (NO) end-products in urine and evaluating inducible nitric oxide synthase (iNOS) expression immunohistochemically, we were able to show that IFN-alpha may induce urothelial iNOS expression with subsequent formation of peroxynitrite, which might contribute to the antineoplastic action of IFN-alpha. Bacillus Calmette-Guerin (BCG) is thought to bind to the bladder wall via interaction between the bacterial antigen 85 complex and fibronectin. Although systemic reactions (evolution of cellular immune response, systemic production of cytokines and oxygen free radicals) have been reported, a likely scenario is that exposure to BCG results in a massive local immune response, characterized by induced expression of cytokines in the urine and in the bladder wall, and by a marked infiltration of the bladder wall by granulocytes and mononuclear cells. BCG-induced changes in tumor cell phenotype render them able to act both as lymphokine-alphactivated killer cell targets and antigen presenting cells. Although BCG may act directly on the proliferation of tumor cells, helper and cytotoxic T cells and, most probably, NK cells are absolutely necessary for any antitumor effects. Tumor cell killing is mediated through FasLigand, perforin and TNF-alpha. In a recent study, we found that BCG up-regulated iNOS expression in normal human urothelium in vivo, suggesting a role for NO in BCG-mediated antitumor activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15875784

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  13 in total

1.  Investigation of granulomatous prostatitis incidence following intravesical BCG therapy.

Authors:  Mehmet Balasar; Metin Doğan; Abdulkadir Kandemir; Hakan Hakki Taskapu; Faruk Cicekci; Hatice Toy; Recai Gurbuz
Journal:  Int J Clin Exp Med       Date:  2014-06-15

2.  Urinary tuberculosis is associated with the development of urothelial carcinoma but not renal cell carcinoma: a nationwide cohort study in Taiwan.

Authors:  Y-C Lien; J-Y Wang; M-C Lee; C-C Shu; H-Y Chen; C-H Hsieh; C-H Lee; L-N Lee; K-M Chao
Journal:  Br J Cancer       Date:  2013-10-15       Impact factor: 7.640

3.  Infection of an axillo-bifemoral bypass graft following intravesical bacillus Calmette-Guerin (BCG) immunotherapy for urothelial cancer due to Mycobacterium bovis and Staphylococcus aureus.

Authors:  Daniel C DeSimone; Aaron J Tande
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2016-09-16

4.  Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Tokyo.

Authors:  Akira Kitamura; Sohkichi Mastumoto; Izumi Asahina
Journal:  Cancer Cell Int       Date:  2009-12-02       Impact factor: 5.722

5.  Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins.

Authors:  Marcia R Saban; Helen L Hellmich; Cindy Simpson; Carole A Davis; Mark L Lang; Michael A Ihnat; Michael A O'Donnell; Xue-Ru Wu; Ricardo Saban
Journal:  BMC Cancer       Date:  2007-11-02       Impact factor: 4.430

6.  Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG).

Authors:  Marcia R Saban; Cindy Simpson; Carole Davis; Gemma Wallis; Nicholas Knowlton; Mark Barton Frank; Michael Centola; Randle M Gallucci; Ricardo Saban
Journal:  BMC Immunol       Date:  2007-05-16       Impact factor: 3.615

7.  Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-alpha.

Authors:  Marcia R Saban; Michael A O'Donnell; Robert E Hurst; Xue-Ru Wu; Cindy Simpson; Igor Dozmorov; Carole Davis; Ricardo Saban
Journal:  BMC Immunol       Date:  2008-02-11       Impact factor: 3.615

8.  Mycobacterium bovis BCG promotes tumor cell survival from tumor necrosis factor-α-induced apoptosis.

Authors:  Sahana Holla; Devram Sampat Ghorpade; Vikas Singh; Kushagra Bansal; Kithiganahalli Narayanaswamy Balaji
Journal:  Mol Cancer       Date:  2014-09-11       Impact factor: 27.401

9.  Systemic BCG-osis following intravesical BCG instillation for bladder carcinoma.

Authors:  Frank Liaw; Yan Yu Tan; David Hendry
Journal:  Clin Case Rep       Date:  2017-08-15

10.  Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome.

Authors:  R Waked; J Choucair; N Chehata; E Haddad; G Saliba
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2020-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.